August 6, 2026 — Yeasen Biotechnology Co., Ltd. ("Yeasen") and Porton Advanced Solutions Ltd. ("Porton Advanced") today announced a strategic partnership. The collaboration will focus on custom transfection reagent development, joint quality control product validation, and market synergies to bridge upstream critical raw materials with CDMO services, delivering more efficient and cost-competitive one-stop cell and gene therapy (CGT) solutions to global clients.
At the signing ceremony, Weihua Huang, Founder and Chairman of Yeasen, and CEO of Porton Advanced, signed the strategic cooperation agreement on behalf of both parties. The signing was also witnessed by Guosheng Tan, General Manager of Yeasen’s Biomedical Business Unit; Yuzhen Fan, Director of Biomedical Products at Yeasen; Wei Guo, Director of Viral R&D and Production at Porton Advanced; and other senior executives.
01 Complementary Strengths: Building a New Industry Ecosystem
As the CGT industry enters its critical commercialization phase, supply chain security for core raw materials has become a strategic priority. Yeasen brings deep expertise in molecular enzymes and quality control reagents, with core products—including transfection reagents and detection kits—developed and manufactured at scale in-house, widely deployed across life science research and biomedical applications. As a leader in the CGT CDMO space, Porton Advanced operates an end-to-end platform spanning plasmids, viral vectors, cell therapy, gene therapy, nucleic acids, and exosome products, offering full-lifecycle services from IND filing and clinical research through to commercial manufacturing. This partnership leverages the complementary strengths of both companies—upstream critical raw materials from Yeasen and downstream CMC development and production from CEO of Porton Advanced—to create seamless integration across the value chain and build a more robust supply chain ecosystem for the industry.
02 Raw Material Synergy: Accelerating Industry Progress
The two companies have already established a strong working relationship in transfection reagents and quality control products. This strategic partnership aims to deepen collaboration, complement each other’s strengths, and share resources to jointly build a closed-loop service system covering reagent R&D, process optimization, and quality control—further enhancing CGT drug development efficiency and manufacturing productivity while strengthening both parties’ competitive position across the biomedical value chain.
Under the cooperation framework, the two parties will deepen collaboration across three key areas: development and supply of high-performance transfection reagents, joint validation and application of quality control products, and synergies in technology, R&D, and market outreach. Yeasen will leverage its core raw material R&D and large-scale supply capabilities, while Porton Advanced brings process development and validation expertise drawn from real-world CDMO projects and GMP manufacturing environments—together driving continuous product optimization and industrial adoption. Both companies will also strengthen resource alignment through technical exchanges, project collaboration, and industry events to jointly expand their footprint in the CGT space.
03 Shared Vision: Leadership Perspectives on the Partnership
Weihua Huang, Founder and Chairman of Yeasen, commented:
“Porton Advanced is a recognized leader in China’s CGT CDMO sector, with outstanding platform capabilities and a strong track record of project delivery. We are delighted to enter into this strategic partnership. Yeasen has always been committed to delivering high-quality enabling products, and this collaboration will embed us more deeply into the CGT drug development value chain, accelerating the validation and adoption of core raw materials in real-world manufacturing settings. By harnessing our raw material and technology strengths, we look forward to helping Porton Advanced and our shared customers reduce costs, improve efficiency, and create greater value together.”
Andrew Chen, CEO of Porton Advanced, stated,“Yeasen brings an advanced technology platform and high-quality products that are highly complementary to our CDMO platform, particularly in transfection and quality control reagents. This strategic partnership not only strengthens the stability and competitiveness of our supply chain but also represents a significant step forward in our efforts to optimize the CGT industry ecosystem. We look forward to working with Yeasen to provide our clients with one-stop services from raw materials to commercial manufacturing, fulfilling our mission of making good medicines available to patients sooner.”
04 Moving Forward Together: Empowering Industry Innovation
This strategic partnership marks a new beginning for win-win growth between both companies. Looking ahead, Yeasen and Porton Advanced will move forward together, combining their enhanced integrated service capabilities to empower innovative biopharmaceutical companies worldwide and drive the sustained growth of the CGT industry.
About Porton Advanced
Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, Investigator-initiated Clinical Trial Services (IITs), and Investigational New Drug (IND) applications to clinical trials, New Drug Applications (NDA), and commercialization.
Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV, etc.), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc., bacterial vector and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sq ft, equipped with 10 viral vector GMP-compliant production lines, 12 cell therapy GMP-compliant production suites (2 for commercial products). As of now, we have successfully supported our clients to secure 26 global IND approvals from NMPA, FDA, and Medsafe, with 12 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China.
Porton Advanced is committed to a customer-centric approach, offering excellent global, end-to-end CDMO services to our clients, enabling earlier access to good medicines.
About Yeasen
Yeasen Biotechnology is a leading biotechnology company specializing in protein engineering and directed evolution technology. Since its establishment in 2014, Yeasen has been dedicated to the advancement of molecular enzymes and proteins within the life science sector. Leveraging our proprietary materials, we have undertaken the development of enzyme and reagents across three key categories: molecules, proteins, and cellular biology. These products cater to the demands of the life science research, molecular diagnostics, and biopharmaceutical industries. Over more than 10 years, Yeasen has evolved into a distinguished international high-tech enterprise, boasting self-reliant research and development as well as manufacturing capabilities.
